

amended by section 1075(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act.<sup>6</sup> This provision requires the Board, at least once every two years,<sup>7</sup> to disclose aggregate or summary information concerning the costs incurred and interchange transaction fees charged or received by issuers or payment card networks in connection with the authorization, clearance, or settlement of electronic debit transactions as the Board considers appropriate and in the public interest.<sup>8</sup> It also provides the Board with authority to require issuers and payment card networks to provide information to enable the Board to carry out the provisions of the subsection.<sup>9</sup> The FR 3064 surveys are mandatory.

The Board is required to release aggregate information from responses to the FR 3064 surveys.<sup>10</sup> The Board additionally releases, at the network level, the percentage of total number of transactions, the percentage of total value of transactions, and the average transaction value for exempt and non-exempt issuers obtained on the FR 3064b because it can be calculated based on information the Board already releases and may be useful to issuers, merchants, and policymakers in choosing payment card networks and assessing the effects of interchange regulations. The information contained in individual responses to the FR 3064 surveys is nonpublic commercial or financial information, which is both customarily and actually treated as private by the respondent. The Board therefore keeps such information confidential pursuant to exemption 4 of the Freedom of Information Act (FOIA).<sup>11</sup>

Board of Governors of the Federal Reserve System, July 7, 2022.

**Michele Taylor Fennell,**

*Deputy Associate Secretary of the Board.*

[FR Doc. 2022-14870 Filed 7-12-22; 8:45 am]

**BILLING CODE 6210-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[CDC-2019-0015, Docket Number NIOSH-153-E]

**Publication of Skin Notation Profile Documents for Chlorodiphenyl (54% Chlorine) (CAS: 11097-69-1), Diacetyl and 2,3-Pentanedione (CAS: 431-03-8; 600-14-6), Dioxane (CAS: 123-91-1), Beta Chloroprene (CAS: 126-99-8), and 2,4-Toluene Diisocyanate, 2,6-Toluene Diisocyanate, and 2,4- and 2,6-Toluene Diisocyanate Mixture (CAS: 584-84-9; 91-08-7; 26471-62-5 (as a Mixture))**

**AGENCY:** The Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of availability.

**SUMMARY:** The National Institute for Occupational Safety and Health (NIOSH) in the Centers for Disease Control and Prevention (CDC), an operating division of the Department of Health and Human Services (HHS), announces the availability of five documents, the *Skin Notation Profiles for Chlorodiphenyl (54% chlorine) (CAS: 11097-69-1), Diacetyl and 2,3-Pentanedione (CAS: 431-03-8; 600-14-6), Dioxane (CAS: 123-91-1), beta Chloroprene (CAS: 126-99-8), and 2,4-Toluene diisocyanate, 2,6-Toluene diisocyanate, and 2,4- and 2,6-Toluene diisocyanate mixture (CAS: 584-84-9; 91-08-7; 26471-62-5 (as a mixture))*.

**DATES:** The final documents were published on July 7, 2022 on the CDC website.

**ADDRESSES:** The documents may be obtained at the following links:

Chlorodiphenyl (54% chlorine) (CAS: 11097-69-1): <https://www.cdc.gov/niosh/docs/2022-118/>;

Diacetyl and 2,3-Pentanedione (CAS: 431-03-8; 600-14-6): <https://www.cdc.gov/niosh/docs/2022-116/>;

Dioxane (CAS: 123-91-1): <https://www.cdc.gov/niosh/docs/2022-114/>;

beta Chloroprene (CAS: 126-99-8): <https://www.cdc.gov/niosh/docs/2022-115/>;

2,4-Toluene diisocyanate, 2,6-Toluene diisocyanate, and 2,4- and 2,6-Toluene diisocyanate mixture (CAS: 584-84-9; 91-08-7; 26471-62-5 (as a mixture)): <https://www.cdc.gov/niosh/docs/2022-117/>.

#### FOR FURTHER INFORMATION CONTACT:

Naomi Hudson, NIOSH, 1090 Tusculum Ave., MS C-15, Cincinnati, OH 45226; Telephone 513-533-8388; Email: [iuz8@cdc.gov](mailto:iuz8@cdc.gov).

**SUPPLEMENTARY INFORMATION:** On March 15, 2019, NIOSH published a request for public comment in the **Federal Register** [Federal Register Number 2019-04794] [84 FR 9524] on the draft versions of the following skin notation profile documents:

Beta-Chloroprene (CAS: 126-99-8)

Cyclohexanol (CAS: 108-93-0)

Cyclohexanone (CAS: 108-94-1)

Cyclonite (CAS: 121-82-4)

Dioxane (CAS: 123-91-1)

Diacetyl/2,3-Pentanedione (CAS: 431-03-8; 600-14-6)

Diethylenetriamine (CAS: 111-40-0)

Chlorodiphenyl (42% chlorine) (CAS: 53469-21-9)

Chlorodiphenyl (54% chlorine) (CAS: 11097-69-1)

Toluene diisocyanates (CAS: 584-84-9; 91-08-7; 26471-62-5)

This notice announces that five of these documents have been finalized and published: *Chlorodiphenyl (54% chlorine) (CAS: 11097-69-1), Diacetyl and 2,3-Pentanedione (CAS: 431-03-8; 600-14-6), Dioxane (CAS: 123-91-1), beta Chloroprene (CAS: 126-99-8), and 2,4-Toluene diisocyanate, 2,6-Toluene diisocyanate, and 2,4- and 2,6-Toluene diisocyanate mixture (CAS: 584-84-9; 91-08-7; 26471-62-5 (as a mixture))*. All comments received were carefully reviewed and addressed, where relevant. In response to comments received, revisions were made to clarify the data used by NIOSH in its support of the development of the skin notation assignments for these chemicals. NIOSH Skin Notation Profiles, Group E Responses to Peer Review and Public Comments can be found in the Supporting Documents section on [www.regulations.gov](http://www.regulations.gov) for the CDC-2019-0015 docket.

The other five documents were previously published in the **Federal Register** [Federal Register Number 2020-25300] [85 FR 73481] on November 18, 2020 (<https://www.federalregister.gov/documents/2020/11/18/2020-25300/skin-notation-profiles-for-chlorodiphenyl-42-chlorine-cas-53469-21-9-cyclohexanol-cas-108-93-0>): Chlorodiphenyl (42% chlorine) (CAS: 53469-21-9), Cyclohexanol (CAS: 108-93-0), Cyclohexanone (CAS: 108-94-1), Cyclonite (CAS: 121-82-4), and Diethylenetriamine (CAS: 111-40-0).

**John J. Howard,**

*Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.*

[FR Doc. 2022-14906 Filed 7-12-22; 8:45 am]

**BILLING CODE 4163-18-P**

<sup>6</sup> 12 U.S.C. 1693o-2.

<sup>7</sup> The subsection refers to bi-annual disclosures and the Board interprets this to mean once every two years. See 76 FR 43458.

<sup>8</sup> 15 U.S.C. 1693o-2(a)(3)(B).

<sup>9</sup> *Id.*

<sup>10</sup> *Id.*

<sup>11</sup> 5 U.S.C. 552(b)(4).